OrganaBio LLC and RxMP Therapeutics have entered into a strategic manufacturing partnership to advance the development of RMP-402, an investigational therapy designed to rapidly control severe haemorrhage.

Under the agreement, OrganaBio will act as the contract manufacturing partner, providing technology transfer, process qualification and current Good Manufacturing Practice (cGMP) production for RMP-402. The collaboration combines OrganaBio’s expertise in manufacturing, quality systems and analytical development with RxMP’s proprietary haemostatic platform technology.

RMP-402 is a first-in-class therapeutic composed of engineered allogeneic red blood cell membrane particles. These particles are designed to mimic naturally occurring components in human blood and rapidly stop bleeding when administered intravenously, without increasing the risk of unwanted clot formation. The therapy is being developed for both civilian trauma care and military applications, addressing a significant unmet need in managing life-threatening bleeding.

The partnership follows regulatory progress by RxMP, including alignment with the U.S. Food and Drug Administration on its proposed manufacturing process. The company has also entered into a research collaboration with the U.S. Department of Defense’s Institute of Surgical Research to further evaluate the therapy’s potential in treating combat-related injuries.

Executives from both companies highlighted the importance of the collaboration in accelerating the therapy’s development timeline. OrganaBio stated that its integrated infrastructure and quality-driven approach will help ensure reliable and scalable manufacturing, while RxMP emphasised that the partnership allows it to focus on regulatory strategy and clinical advancement.

Uncontrolled bleeding remains a leading cause of preventable death worldwide, particularly in trauma and surgical settings. With a global market estimated at billions of dollars annually, RMP-402 is positioned as a potential breakthrough solution aimed at improving patient outcomes and reducing mortality.

OrganaBio LLC continues to expand its capabilities in cell and gene therapy manufacturing, while RxMP Therapeutics advances its pipeline focused on innovative treatments for acute bleeding conditions.